EN
中文 EN
Newsroom
Company News
Media Report
Company News
More
2025-06-20
CanSinoBIO Obtained NDA Approval for its 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine iPneucia®
CanSinoBIO Launches First-in-Class Three-Component LNP Delivery System: Enhances T Cell Response and Safety, Surpassing Industry Patent Barriers
2025-06-17
CanSinoBIO Obtained Approval for Clinical Trials of Inhaled TB Vaccine in Indonesia
2025-05-15
SPIMACO and CanSinoBIO Sign an Agreement to Localise and Market the MCV4 Vaccine in Saudi Arabia and MENA
2025-03-26
Professor Adrian V. S. Hill FRS from Oxford University Visits CanSinoBIO, Highlights Vaccine Innovations
2025-03-21
CanSinoBIO Obtained Approval for Clinical Trials on DTcP-Hib-MCV4 Combined Vaccine
2025-02-24
Media Report
More
Revenue Soars with 137% Year-on-Year Growth, Multiple Products Poised for Launch, CanSinoBIO's Growth Momentum Strong
Time：2025-03-28
More
CanSinoBIO to Showcase China’s Vaccine Innovation at 2025 World Government Summit in Dubai
Time：2025-02-14
More
CanSinoBIO Secures Further Funding from the Bill & Melinda Gates Foundation
Time：2024-10-09Source：ACN Newswire
More